Acute exudative polymorphous vitelliform maculopathy during pembrolizumab treatment for metastatic melanoma Vrije Universiteit Brussel
BACKGROUND: The use of immunomodulating therapy to treat various cancers has been on the rise and these immune checkpoint inhibitors are known to cause ocular side effects. In this article a case of acute exudative polymorphous vitelliform maculopathy (AEPVM) is reported which developed during a first line treatment with pembrolizumab.
CASE PRESENTATION: A 54-year-old woman was referred because of blurry vision in both eyes with a ...